NCT01446562View on ClinicalTrials.gov

Y90 Ibritumomab Tiuxetan Post R-CHOP Chemotherapy for Advanced Stage Follicular Lymphoma

PHASE2CompletedINTERVENTIONAL
Enrollment

34

Participants

Timeline

Start Date

May 31, 2007

Primary Completion Date

May 31, 2016

Study Completion Date

May 31, 2016

Conditions
Follicular Lymphoma
Interventions
BIOLOGICAL

Y90 Ibritumomab Tiuxetan RIT

40 mCi/kg

Trial Locations (1)

M4N 3M5

Sunnybrook Health Sciences Centre, Odette Cancer Centre, Toronto

All Listed Sponsors
lead

Sunnybrook Health Sciences Centre

OTHER

NCT01446562 - Y90 Ibritumomab Tiuxetan Post R-CHOP Chemotherapy for Advanced Stage Follicular Lymphoma | Biotech Hunter | Biotech Hunter